Nontuberculous mycobacterium as a hidden cause of noncystic fibrosis bronchiectasis

Darwish, Atef M.; Mahalawy, Ibrahim El; Dahdouh, Samy S.A El; Elkholy, Reem Mohsen; Beshbishy, Mahmoud I.A El

doi:10.4103/ejcdt.ejcdt_75_19

Cited by 3 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven out of 21 (33.3%) included studies reported a broad range of clinical symptoms, disease characteristics (i.e., age, sex, weight, and height), radiological patterns, and microbiological data to identify the clinical markers associated with NTM isolation in bronchiectasis [5, 17, 24‒26, 29, 32]. An overview of all clinical markers that have been reviewed is presented in online suppl.…”

Section: Resultsmentioning

confidence: 99%

“…Our review presented a slightly lower prevalence of NTM isolation in bronchiectasis than the previous systematic review that reported an overall prevalence of 9.3% in 8 studies [12]. Since publication of this systematic review, 16 new relevant studies have been published [5, 7, 8, 17‒26, 28‒30, 35]. It is also worth noting that we only included studies written in English and using objective and valid methods to validate bronchiectasis and NTM isolation rather than self-reported or medical record review, given the low sensitivity of diagnosis code-based claims to identify NTM.…”

Section: Discussionmentioning

confidence: 96%

“…Upon further review, 1,490 abstracts or articles were rejected for not meeting inclusion criteria or meeting exclusion criteria. Of the 34 full-text articles reviewed, 21 articles, which reported the prevalence of NTM isolation or NTM-PD were included [5,7,8,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]. No additional articles were identified from manually reviewing the reference lists of included articles.…”

Section: Study Attrition and Characteristicsmentioning

confidence: 99%

“…Finally, 21 articles were included for the final metaanalysis (Fig. 1) [5,7,8,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]. Details regarding excluded studies have been shown in online suppl.…”

Section: Study Attrition and Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Prevalence and Clinical Characteristics of Nontuberculous Mycobacteria in Patients with Bronchiectasis: A Systematic Review and Meta-Analysis

Zhu

Xie

et al. 2021

Respiration

View full text Add to dashboard Cite

Background: Although international bronchiectasis guidelines recommended screening of nontuberculous mycobacteria (NTM) both at initial evaluation and prior to administration of macrolide treatment, data regarding NTM in bronchiectasis remain elusive. Objective: To establish the prevalence, species, and clinical features of NTM in adults with bronchiectasis. Methods: We searched PubMed, Embase, and Web of Science for studies published before April 2020 reporting the prevalence of NTM in adults with bronchiectasis. We only included studies with bronchiectasis confirmed by computed tomography and NTM identified by mycobacteria culture or molecular methods. Random-effects meta-analysis was employed. Results: Of the 2,229 citations identified, 21 studies, including 12,454 bronchiectasis patients were included in the final meta-analysis. The overall pooled prevalence of NTM isolation and pulmonary NTM disease were 7.7% (5.0%–11.7%) (n/N = 2,677/12,454) and 4.1% (1.4%–11.4%) (n/N = 30/559), respectively, with significant heterogeneity (I2 = 97.7%, p < 0.001 and I2 = 79.9%, p = 0.007; respectively). The prevalence of NTM isolation varied significantly among different geographical regions with the highest isolation at 50.0% (47.3%–52.7%) reported in the United States. Mycobacterium avium complex and Mycobacterium abscessus complex accounted for 66 and 16.6% of all species, respectively. Some clinical and radiological differences were noted between patients with and without the presence of NTM isolation although the results are inconsistent. Conclusions: Heterogeneity in prevalence estimates of NTM isolation indicated that both local surveys to inform development of clinical services tailored to patients with bronchiectasis and population-based studies are needed. The clinical features associated with NTM in bronchiectasis and their incremental utility in studying the association is unknown and merits further investigation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 96%

Section: Study Attrition and Characteristicsmentioning

confidence: 99%

Section: Study Attrition and Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence and Clinical Characteristics of Nontuberculous Mycobacteria in Patients with Bronchiectasis: A Systematic Review and Meta-Analysis

Zhu

Xie

et al. 2021

Respiration

View full text Add to dashboard Cite

show abstract

Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006–2021: a systematic review and meta-analysis

Zhou

Zhang

et al. 2022

BMJ Open

View full text Add to dashboard Cite

ObjectiveTo accurately estimate the global prevalence of non-tuberculous mycobacteria (NTM) in adults with non-cystic fibrosis (non-CF) bronchiectasis and to determine the proportion of NTM species and subspecies in clinical patients from 2006 to 2021.DesignSystematic review and meta-analysis using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.Data sourcesMedline, Embase, Cochrane Library and Web of Science were searched for articles published between 2006 and 2021.Eligibility criteria for selecting studiesWe included all the prospective or retrospective studies without language restrictions and all patients were adults (≥18 years of age) with non-CF bronchiectasis. The studies estimated the effect size of the prevalence of NTM with a sample size ≥40, and patients were registered in and after 2006.Data extraction and synthesisTwo reviewers screened the titles, abstracts and full texts independently. Relevant information was extracted and curated into tables. Risk of bias was evaluated following the Cochrane Collaboration’s tool. Meta-analysis was performed with software R Statistics V.3.6.3 using random effect model with 95% CI. I2 index and Q statistics were calculated to assess the heterogeneity, and mixed-effects meta-regression analyses were performed to identify the sources of heterogeneity. The proportions of NTM subspecies were examined using Shapiro-Wilk normality test in R.ResultsOf all the 2014 studies yielded, 24 met the inclusion criteria. Of these, 14 were identified to be randomised controlled studies and included for an accurate estimation. The global prevalence of NTM in adults with non-CF bronchiectasis from 2006 to 2021 was estimated to be approximately 10%, with great variations primarily due to geographical location. Mycobacterium avium complex was the most common subspecies, followed by Mycobacterium simiae and Mycobacterium gordonae.ConclusionsThe prevalence of NTM in adults with non-CF bronchiectasis has been on the rise and the most common subspecies changed greatly in recent years. More cohort studies should be done in many countries and regions for future estimates.PROSPERO registration numberCRD42020168473.

show abstract

5-Alkylamino-N-phenylpyrazine-2-carboxamides: Design, Preparation, and Antimycobacterial Evaluation

et al. 2020

View full text Add to dashboard Cite

According to the World Health Organization, tuberculosis is still in the top ten causes of death from a single infectious agent, killing more than 1.7 million people worldwide each year. The rising resistance developed by Mycobacterium tuberculosis against currently used antituberculars is an imperative to develop new compounds with potential antimycobacterial activity. As a part of our continuous research on structural derivatives of the first-line antitubercular pyrazinamide, we have designed, prepared, and assessed the in vitro whole cell growth inhibition activity of forty-two novel 5-alkylamino-N-phenylpyrazine-2-carboxamides with various length of the alkylamino chain (propylamino to octylamino) and various simple substituents on the benzene ring. Final compounds were tested against Mycobacterium tuberculosis H37Ra and four other mycobacterial strains (M. aurum, M. smegmatis, M. kansasii, M. avium) in a modified Microplate Alamar Blue Assay. We identified several candidate molecules with micromolar MIC against M. tuberculosis H37Ra and low in vitro cytotoxicity in HepG2 cell line, for example, N-(4-hydroxyphenyl)-5-(pentylamino)pyrazine-2-carboxamide (3c, MIC = 3.91 µg/mL or 13.02 µM, SI > 38) and 5-(heptylamino)-N-(p-tolyl)pyrazine-2-carboxamide (4e, MIC = 0.78 µg/mL or 2.39 µM, SI > 20). In a complementary screening, we evaluated the in vitro activity against bacterial and fungal strains of clinical importance. We observed no antibacterial activity and sporadic antifungal activity against the Candida genus.

show abstract

Nontuberculous mycobacterium as a hidden cause of noncystic fibrosis bronchiectasis

Cited by 3 publications

References 2 publications

Prevalence and Clinical Characteristics of Nontuberculous Mycobacteria in Patients with Bronchiectasis: A Systematic Review and Meta-Analysis

Prevalence and Clinical Characteristics of Nontuberculous Mycobacteria in Patients with Bronchiectasis: A Systematic Review and Meta-Analysis

Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006–2021: a systematic review and meta-analysis

5-Alkylamino-N-phenylpyrazine-2-carboxamides: Design, Preparation, and Antimycobacterial Evaluation

Contact Info

Product

Resources

About